[PDF][PDF] Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in …
J Baselga, JM Trigo, J Bourhis, J Tortochaux… - Journal of clinical …, 2005 - academia.edu
J Baselga, JM Trigo, J Bourhis, J Tortochaux, H Cortés-Funes, R Hitt, P Gascón, N Amellal…
Journal of clinical oncology, 2005•academia.eduPurpose To evaluate the efficacy and safety of the antiepidermal growth factor receptor
monoclonal antibody cetuximab in combination with platinum-based chemotherapy in
patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the
head and neck (SCCHN).
monoclonal antibody cetuximab in combination with platinum-based chemotherapy in
patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the
head and neck (SCCHN).
Conclusion
The combination of cetuximab and platinum chemotherapy is an active and well-tolerated approach to the treatment of this poor-prognosis patient population with platinumrefractory recurrent or metastatic SCCHN for whom there are no recommended standard therapeutic options.
academia.edu